Axa
PACB icon

Axa’s Pacific Biosciences PACB Stock Holding History

Axa’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-165,900
Closed -$1.49M – 1281
2016
Q3 		$1.49M Sell
165,900
-6,400
-4% -$53.5K 0.01% 825
2016
Q2 		$1.21M Buy
172,300
+133,400
+343% +$1.22M 0.01% 836
2016
Q1 		$331K Buy
+38,900
New +$383K ﹤0.01% 1070

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Axa's PACB Position: Q4 2016 in Review

Axa sold out of Pacific Biosciences (PACB) in Q4 2016, closing a stake of 165,900 shares — an estimated $1.49M sold.

Axa first reported a position in PACB in Q1 2016 and held it in 3 quarters. The position peaked at $1.49M in Q3 2016. 115 funds tracked by Wall St. Rank hold PACB as of Q4 2016.

  • Axa reported no remaining Pacific Biosciences position as of Q4 2016 after selling out during the quarter.
  • Axa sold 165,900 Pacific Biosciences shares in Q4 2016, an estimated $1.49M.
  • Axa first reported a position in Pacific Biosciences in Q1 2016 and held it in 3 quarters.
  • Axa's Pacific Biosciences position peaked at $1.49M in Q3 2016.
  • 115 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2016.

Based on Axa's 13F filing for Q4 2016, filed 13 Feb 2017.